Pardes Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
May 10, 2022 16:01 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...
Pardes Biosciences Reports Full Year 2021 Financial Results and Provides Business Update
March 29, 2022 16:05 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...
Pardes Biosciences to Present at the International Conference On Antiviral Research 2022
March 21, 2022 07:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif. , March 21, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel...
Pardes Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 04, 2022 16:30 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel...
Pardes Biosciences to Present at Cowen Healthcare Conference
March 03, 2022 07:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel...
Pardes Biosciences Appoints Thomas G. Wiggans to CEO and Chairman of the Board
March 02, 2022 16:30 ET
|
Pardes Biosciences, Inc
Mr. Wiggans brings over 40 years of biopharmaceutical industry experience, including over 25 years in chief executive leadership roles with multiple successful acquisitions. His expertise will be...
Pardes Biosciences Presents Interim Clinical Data from Ongoing PBI-0451 Phase 1 Trial Supporting the Potential of PBI-0451 as a Stand-Alone Oral Regimen for COVID-19 at Conference on Retroviruses and Opportunistic Infections 2022
February 14, 2022 07:30 ET
|
Pardes Biosciences, Inc
PBI-0451 administered twice-daily as a stand-alone agent achieves and maintains PK exposures anticipated to provide potent antiviral activity against SARS-CoV-2 PBI-0451 has been generally...
Pardes Biosciences to Host Virtual Investor Event
February 09, 2022 07:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral...
Pardes Biosciences to Present Clinical Data from Ongoing PBI-0451 Phase 1 Trial at Conference On Retroviruses And Opportunistic Infections 2022
February 08, 2022 07:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral...
Pardes Biosciences Announces FDA Clearance of IND Application for PBI-0451, an Oral Antiviral Drug Candidate for the Treatment and Prevention of SARS-CoV-2 Infections
February 03, 2022 07:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral...